Last reviewed · How we verify
Oxytrol
At a glance
| Generic name | Oxytrol |
|---|---|
| Sponsor | Jewish General Hospital |
| Target | Cytochrome P450 2C19, 5-hydroxytryptamine receptor 2B, D(3) dopamine receptor |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Bladder muscle dysfunction - overactive
- Hyperhidrosis of palms
- Increased Urinary Frequency
- Neurogenic bladder
- Urge incontinence of urine
- Urgent desire to urinate
Common side effects
- Application site pruritus
- Application site erythema
- Dry mouth
- Application site vesicles
- Diarrhea
- Dysuria
- Application site rash
- Application site macules
- Abnormal vision
- Constipation
- Severe application site reactions
- Memory impairment
Key clinical trials
- Oxybutynin ER to Promote Early Continence Recovery After Robotic Prostatectomy: A Randomized Controlled Trial (NA)
- A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats
- The Combination of Pharmacotherapy and Cognitive Behavioral Psychotherapy Under the Recovery Perspective. (PHASE1)
- Τhe Combination of Pharmacotherapy With RECOVERYTRSGR and RECOVERYTRSBDGR. (PHASE4)
- Evaluate the Safety and Efficacy of TRG-200 KIT in Patients With Refractory Overactive Bladder. (PHASE2)
- Oxybutynin for Post-surgical Bladder Pain and Urgency (PHASE3)
- Behavioral Interventions Versus Pelvic Floor Muscle Therapy as Adjuncts to Anticholinergic Pharmacotherapy for Urgency Urinary Incontinence: A Non-Inferiority Trial (NA)
- Prospective Trial Comparing Oxybutynin and Tamsulosin for Stent Pain in the Pediatric Population (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oxytrol CI brief — competitive landscape report
- Oxytrol updates RSS · CI watch RSS
- Jewish General Hospital portfolio CI